So the FDA made an announcement: Its launching what it calls a green list of GLP-1 APIs from overseas facilities that the agency has inspected or evaluated that appear to be in compliance with the FDAs rigorous standards. GLP-1s coming from other sources will be subject to detention without physical examination. Some media outlets looking at you, Axios made it sound as if this green list was all about compounded drugs (and, to be fair, the FDA did throw a little unnecessary shade on compounding)
Ketogenic dietary interventions in autosomal dominant polycystic kidney disease-a retrospective case series study: first insights into feasibility, safety and effects
Gasiorowska A, Wydrych M, Drapich P, Zadrozny M, Steczkowska M, Niewiadomski W, Niewiadomska G (2021) The biology and pathobiology of glutamatergic, cholinergic, and dopaminergic signaling in the aging brain
Pancreatitis associated with Victoza has been reported in post-marketing reports